GBC-002
HER2‑positive solid tumors
Pre‑clinicalActive
Key Facts
Indication
HER2‑positive solid tumors
Phase
Pre‑clinical
Status
Active
About General Biologicals Corporation
Taiwan’s fast‑growing CDMO delivering end‑to‑end biologics manufacturing for oncology and immunology.
View full company profileTherapeutic Areas
Other HER2‑positive solid tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NG-101 | Nanogen Pharmaceutical Biotechnology | Preclinical |